Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 44 of 73 for:    HYDROCHLOROTHIAZIDE AND LOSARTAN

Comparision of Blood Pressure Variability Between Amlodipine and Losartan

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01964079
Recruitment Status : Completed
First Posted : October 17, 2013
Last Update Posted : May 12, 2017
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
Byung-Su Yoo, Wonju Severance Christian Hospital

Brief Summary:

Blood pressure (BP) is believed to be a major determinant of vascular disease, and BP lowering is the most important goal in hypertension treatment. Thus, clinical guidelines for hypertension are mainly focused on lowering mean BP. However, despite an increasing incidence of stroke with age, the association between systolic BP (SBP) and the risk of stroke decreases with age. This disparity highlights a gap in the link between BP and vascular-related diseases (i.e., stroke). In clinical practice, visit-to-visit fluctuations in BP have been largely ignored and are thought to be an unreliable finding, even though this phenomenon is frequently observed. Rothwell et al. demonstrated that the visit-to-visit variability in SBP was a more powerful independent predictor of stroke than mean SBP, and that an increased residual variability in SBP in treated hypertensive patients was also a strong predictor of stroke and coronary events.

Recently updated (2011) hypertension guidelines from the National Institute for Health and Clinical Excellence (NICE) recommend an angiotensin converting enzyme inhibitor (ACEi) [or angiotensin II receptor blocker (ARB)] and calcium-channel blocker (CCB) as a first line drug. Although the significance of BP variability (BPV) has been illustrated, the main focus of the current guidelines is to reduce systolic and diastolic BP, not BPV.

In the X-CELLENT study, a CCB (amlodipine) and thiazide-like diuretic drug (indapamide sustained-release) led to a significant reduction in BPV, compared to an ARB (candesartan). In addition, the CCB showed the most effective reduction in systolic BPV among the antihypertensive drug class in a meta-analysis. However, there are no direct comparison studies of a CCB and ARB on BPV. Thus, we aim to compare the systolic BPV effects of a CCB versus an ARB in essential hypertensive patients. The primary hypothesis is that an ARB is not inferior to a CCB in the reduction of the systolic BPV standard deviation (SD) in essential hypertensive patients.


Condition or disease Intervention/treatment Phase
Hypertension Drug: Amlodipine Drug: Losartan Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 144 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: The COMPAriSon of Systolic Blood Pressure Variability and Central Blood Pressure of Calcium Channel Blocker (Amlodipine) in Comparison With Angiotensin Receptor Blocker (Losartan) in Patients With Essential Hypertension
Actual Study Start Date : April 2013
Actual Primary Completion Date : April 2017
Actual Study Completion Date : May 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: CCB (amlodipine)
For patients who fail to respond to 5 mg oral amlodipine daily, the dose will be titrated up to 10 mg amlodipineh. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (>140 mmHg) or diastolic (>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
Drug: Amlodipine
Eligible subjects will be randomized 1:1 to either an amlodipine or a losartan group by a computer-generated random number table. For patients who fail to respond to 5 mg amlodipine, the dose will be titrated up to 10 mg amlodipine. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (>140 mmHg) or diastolic (>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
Other Name: Norvasc

Active Comparator: ARB (losartan)
For patients who fail to respond to 50 mg oral losartan daily, the dose will be titrated up to 100 mg losartan. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (>140 mmHg) or diastolic (>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
Drug: Losartan
Eligible subjects will be randomized 1:1 to either an amlodipine or a losartan group by a computer-generated random number table. For patients who fail to respond to 50 mg losartan, the dose will be titrated up to 100 mg losartan. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (>140 mmHg) or diastolic (>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
Other Name: Cozaar




Primary Outcome Measures :
  1. SD of visit-to-visit systolic blood pressure variability [ Time Frame: 6 months ]
    Consecutive measured blood pressure values from each visit will be averaged, and the standard deviation (SD) is calculated using the mean systolic blood pressure of each visit.


Secondary Outcome Measures :
  1. Central systolic blood pressure [ Time Frame: 6 months ]
    Measurement of central blood pressure will be performed at randomization and 6 months.

  2. Augmentation index of central blood pressure [ Time Frame: 6 months ]
    Augmentation index of central blood pressure will be measured at randomization and 6 months.

  3. Standard deviation of within-visit systolic blood pressure variability [ Time Frame: 6 months ]
  4. Coefficient of variation of visit-to-visit systolic blood pressure variability [ Time Frame: 6 months ]
    The coefficient of variation (CV) is defined as the standard deviation/mean systolic blood pressure.

  5. Variation independent of the mean of visit-to-visit systolic blood pressure variability [ Time Frame: 6 months ]
    To eliminate the correlation of coefficient variation with mean SBP, we will calculate a further transformed variable, the variation independent of the mean (VIM). The VIM is defined as the standard deviation/mean^x, with x estimated from curve fitting of the data.

  6. 24-h ambulatory blood pressure monitoring [ Time Frame: 6 months ]
  7. Home systolic blood pressure [ Time Frame: 6 months ]
    Home systolic blood pressure will be measured at each scheduled visit.


Other Outcome Measures:
  1. Safety outcome [ Time Frame: 6 months ]
    The number of all adverse events including laboratory tests, ECG changes, and vital signs.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 79 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients aged 20 years or older and below 80 years.
  • Patients who have not previously taken any antihypertensive drugs or have discontinued previous antihypertensive drugs for 2 weeks.
  • Mean SBP ≥140 mmHg or mean diastolic BP ≥ 90 mmHg (blood pressure will be checked at least 2 times in a seated position during the screening period).

Exclusion Criteria:

  • Pregnant women, possible candidate for pregnancy, or breastfeeding women.
  • Known or suspected secondary hypertension.
  • Mean seated SBP ≥ 180 mmHg and/or mean seated diastolic BP ≥ 120 mmHg at any visit.
  • Any clinically significant hepatic impairments.
  • Severe renal impairment (serum creatinine level > 3.0 mg/dL or creatinine clearance < 30 mL/min).
  • Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, or post-renal transplant.
  • Clinically relevant hyperkalemia.
  • Uncorrected volume or sodium depletion.
  • Suspected primary aldosteronism.

    1. Hypertension and spontaneous or low-dose diuretic-induced hypokalemia.
    2. Drug-resistant hypertension, defined as sub-optimally controlled hypertension on a 3-drug program that includes an adrenergic inhibitor, vasodilator, and diuretic.
    3. Hypertension with adrenal incidentaloma.
    4. Hypertension and a family history of early-onset hypertension or cerebrovascular accident at a young age (<40 years).
    5. Hypertensive first-degree relatives of patients with primary aldosteronism.
  • Symptomatic congestive heart failure.
  • Angina pectoris requiring treatment.
  • History of myocardial infarction or cerebrovascular accident (ischemic stroke or hemorrhage).
  • History of refractory or potentially lethal arrhythmias.
  • Concurrent participation in another clinical trial.
  • Patients with known intolerance, contraindication, or hypersensitivity to any component of dihydropyridines or angiotensin II receptor blockers.
  • Patients who are deemed unsuitable by the investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01964079


Locations
Layout table for location information
Korea, Republic of
Wonju Severance Christian Hospital
Wonju, Gangwon-do, Korea, Republic of, 220-701
Sponsors and Collaborators
Wonju Severance Christian Hospital
Pfizer
Investigators
Layout table for investigator information
Principal Investigator: Byung-Su Yoo, MD, PhD Wonju Severance Christian Hospital

Layout table for additonal information
Responsible Party: Byung-Su Yoo, Professor, Wonju Severance Christian Hospital
ClinicalTrials.gov Identifier: NCT01964079     History of Changes
Other Study ID Numbers: COMPASS-BPV
First Posted: October 17, 2013    Key Record Dates
Last Update Posted: May 12, 2017
Last Verified: May 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Losartan
Hydrochlorothiazide
Hypertension
Vascular Diseases
Cardiovascular Diseases
Amlodipine
Antihypertensive Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Vasodilator Agents
Anti-Arrhythmia Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Diuretics
Natriuretic Agents
Sodium Chloride Symporter Inhibitors